STOCK TITAN

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

Theriva Biologics (NYSE American: TOVX) announced that the European Commission has granted orphan medicinal product designation to VCN-01, their lead clinical candidate for the treatment of retinoblastoma. VCN-01 is a systemic, selective, stroma-degrading oncolytic adenovirus. This designation follows the FDA's previous orphan drug and rare pediatric disease designations for VCN-01 in retinoblastoma treatment.

The company has reported encouraging results from a Phase 1 trial evaluating intravitreal VCN-01 in pediatric patients with refractory retinoblastoma. Theriva is collaborating with physicians and regulatory agencies to refine their clinical strategy for VCN-01 as an adjunct to chemotherapy in children with retinoblastoma.

The orphan designation provides benefits including 10-years market exclusivity in the EU upon marketing authorization, protocol assistance, administrative support, and reduced regulatory fees.

Theriva Biologics (NYSE American: TOVX) ha annunciato che la Commissione Europea ha concesso la designazione di medicinale orfano a VCN-01, il loro principale candidato clinico per il trattamento del retinoblastoma. VCN-01 è un adenovirus oncolitico sistemico e selettivo che degrada il stroma. Questa designazione segue le precedenti designazioni di farmaco orfano e di malattia pediatrica rara da parte della FDA per VCN-01 nel trattamento del retinoblastoma.

L'azienda ha riportato risultati incoraggianti da uno studio di Fase 1 che ha valutato VCN-01 intravitreo in pazienti pediatrici con retinoblastoma refrattario. Theriva sta collaborando con medici e agenzie regolatorie per perfezionare la loro strategia clinica per VCN-01 come complemento alla chemioterapia nei bambini affetti da retinoblastoma.

La designazione orfana offre vantaggi tra cui 10 anni di esclusività di mercato nell'UE una volta ottenuta l'autorizzazione al commercio, assistenza nella definizione dei protocolli, supporto amministrativo e riduzione delle tasse regolatorie.

Theriva Biologics (NYSE American: TOVX) anunció que la Comisión Europea ha otorgado la designación de medicamento huérfano a VCN-01, su principal candidato clínico para el tratamiento del retinoblastoma. VCN-01 es un adenovirus oncolítico sistémico y selectivo que degrada el estroma. Esta designación sigue a las anteriores designaciones de medicamento huérfano y de enfermedad pediátrica rara por parte de la FDA para VCN-01 en el tratamiento del retinoblastoma.

La compañía ha informado resultados alentadores de un ensayo de Fase 1 que evalúa VCN-01 intravítreo en pacientes pediátricos con retinoblastoma refractario. Theriva está colaborando con médicos y agencias regulatorias para refinar su estrategia clínica para VCN-01 como complemento a la quimioterapia en niños con retinoblastoma.

La designación de huérfano proporciona beneficios que incluyen 10 años de exclusividad de mercado en la UE tras la autorización de comercialización, asistencia con protocolos, apoyo administrativo y reducción de tarifas regulatorias.

Theriva Biologics (NYSE American: TOVX)는 유럽 연합 집행위원회가 VCN-01에 대해 희귀 의약품 지정을 부여했다고 발표했습니다. VCN-01은 망막모세포종 치료를 위한 주요 임상 후보 물질입니다. VCN-01은 전신 사용이 가능한 선택적인 간질을 파괴하는 종양용해 아데노바이러스입니다. 이번 지명은 FDA가 망막모세포종 치료에 대해 VCN-01에 대해 이전에 내린 희귀 약품 및 소아 희귀 질병으로서의 지명에 이어 이루어진 것입니다.

회사는 저항성 망막모세포종을 가진 소아 환자에게서 유리체 내 VCN-01을 평가하는 1상 시험에서 고무적인 결과를 보고했습니다. Theriva는 의사 및 규제 기관들과 협력하여 망막모세포종 아동을 위한 화학 요법의 보조로 VCN-01의 임상 전략을 다듬고 있습니다.

희귀의약품 지명은 마케팅 허가 후 EU에서 10년의 시장 독점권, 프로토콜 지원, 행정 지원 및 규제 수수료 감소 등의 혜택을 제공합니다.

Theriva Biologics (NYSE American: TOVX) a annoncé que la Commission Européenne a accordé la désignation de médicament orphelin à VCN-01, leur principal candidat clinique pour le traitement du rétinoblastome. VCN-01 est un adénovirus oncologique systémique et sélectif qui dégrade le stroma. Cette désignation fait suite aux précédentes désignations de médicament orphelin et de maladie pédiatrique rare par la FDA pour VCN-01 dans le traitement du rétinoblastome.

L'entreprise a rapporté des résultats encourageants d'un essai de Phase 1 évaluant VCN-01 intravitréen chez des patients pédiatriques atteints de rétinoblastome réfractaire. Theriva collabore avec des médecins et des agences réglementaires pour affiner sa stratégie clinique pour VCN-01 en tant qu'adjuvant à la chimiothérapie chez les enfants atteints de rétinoblastome.

La désignation orpheline offre des avantages tels que 10 ans d'exclusivité sur le marché dans l'UE après autorisation de mise sur le marché, assistance aux protocoles, soutien administratif et réduction des frais réglementaires.

Theriva Biologics (NYSE American: TOVX) hat bekannt gegeben, dass die Europäische Kommission der VCN-01 das Orphan-Arzneimittel-Designat verliehen hat, das ihr führendes klinisches Kandidat für die Behandlung des Retinoblastoms ist. VCN-01 ist ein systemischer, selektiver, stroma-abbauender onkolytischer Adenovirus. Diese Auszeichnung folgt auf die vorherigen Orphan-Arzneimittel- und seltenen pädiatrischen Erkrankungen Auszeichnungen der FDA für VCN-01 zur Behandlung des Retinoblastoms.

Das Unternehmen hat ermutigende Ergebnisse aus einer Phase-1-Studie berichtet, in der die intravitrealen Anwendungen von VCN-01 bei pädiatrischen Patienten mit refraktärem Retinoblastom evaluiert wurden. Theriva arbeitet mit Ärzten und Regulierungsbehörden zusammen, um ihre klinische Strategie für VCN-01 als Ergänzung zur Chemotherapie bei Kindern mit Retinoblastom zu verfeinern.

Die orphan Designation bietet Vorteile, darunter 10 Jahre Marktexklusivität in der EU nach Erteilung der Marktzulassung, Protokollhilfe, administrative Unterstützung und reduzierte regulatorische Gebühren.

Positive
  • European Commission granted orphan medicinal product designation to VCN-01 for retinoblastoma treatment
  • FDA previously granted orphan drug and rare pediatric disease designations to VCN-01
  • Encouraging results reported from Phase 1 trial of VCN-01 in pediatric patients with refractory retinoblastoma
  • Orphan designation provides 10-years market exclusivity in the EU upon marketing authorization
Negative
  • None.

Insights

The orphan medicinal product designation granted by the European Commission for VCN-01 in retinoblastoma treatment is a significant milestone for Theriva Biologics. This designation, along with the previously obtained FDA orphan drug and rare pediatric disease designations, underscores the potential of VCN-01 in addressing an unmet medical need.

Key points to consider:

  • Retinoblastoma is a rare and life-threatening pediatric cancer, making new treatment options crucial.
  • VCN-01, as a systemic, selective, stroma-degrading oncolytic adenovirus, represents an innovative approach to treatment.
  • The orphan designation provides 10 years of market exclusivity in the EU upon marketing authorization, which could be a substantial competitive advantage.
  • Additional benefits include protocol assistance and reduced regulatory fees, potentially accelerating development and reducing costs.
  • The previous Phase 1 trial results, while not detailed, are described as "encouraging," suggesting promise for future clinical development.

For investors, this news indicates progress in Theriva's pipeline and potential for future market opportunities in a niche but critical area of oncology. However, it's important to note that significant clinical development and regulatory hurdles remain before commercialization.

ROCKVILLE, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the European Commission has adopted the European Medicines Agency (EMA) recommendation to grant orphan medicinal product designation to lead clinical candidate VCN-01, Theriva’s systemic, selective, stroma-degrading oncolytic adenovirus, for the treatment of retinoblastoma. The United States Food and Drug Administration (FDA) has previously granted orphan drug designation and rare pediatric disease designation to VCN-01 for the treatment of retinoblastoma.

“We are very pleased with the European Commission’s grant of orphan medicinal product designation to VCN-01, emphasizing the urgent need for new treatment options for retinoblastoma,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “We have previously reported encouraging results from an investigator sponsored Phase 1 trial evaluating the safety and activity of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma, and we are working closely with leading physicians and regulatory agencies worldwide to refine our clinical strategy for VCN-01 as an adjunct to chemotherapy in children with this challenging disease.”

The EMA recommends orphan designation for products intended to treat, prevent or diagnose a disease that is life-threatening or chronically debilitating and either the prevalence of the condition in the European Union (EU) does not exceed 5 in 10,000 or it is unlikely that marketing of the product would generate sufficient returns to justify the investment needed for its development. Additionally, there should be no authorizable method of diagnosis, prevention or treatment of the condition, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. Orphan designation is designed to provide drug developers with various benefits to support the development of novel therapies, including 10-years of market exclusivity once they receive marketing authorization in the EU, protocol assistance, administrative and procedural assistance, and reduced fees for regulatory activities.

About Retinoblastoma

Retinoblastoma is a tumor that originates in the retina and is the most common type of eye cancer in children. It occurs in approximately 1/14,000 - 1/18,000 live newborns and accounts for 15% of the tumors in the pediatric population < 1 year old. The average age of pediatric patients at diagnosis is 2, and it rarely occurs in children older than 6. In Europe, retinoblastoma has an estimated incidence rate of 1 per 13,844 live births (14.1 per million children under the age of 5) with approximately 300 children diagnosed per year (Stacey et al. 2021). Preserving life and preventing the loss of an eye, blindness and other serious effects of treatment that reduce the patient’s life span or the quality of life, remains a challenge. In addition, children with retinoblastoma have been more likely to lose their eye and die of metastatic disease in low-resource countries.

About VCN-01

VCN-01 is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma that serves as a significant physical and immunosuppressive barrier to cancer treatment. This unique mode-of-action enables VCN-01 to exert multiple antitumor effects by (i) selectively infecting and lysing tumor cells; (ii) enhancing the access and perfusion of co-administered chemotherapy products; and (iii) increasing tumor immunogenicity and exposing the tumor to the patient’s immune system and co-administered immunotherapy products. Systemic administration enables VCN-01 to exert its actions on both the primary tumor and metastases. VCN-01 has been administered to over 140 patients to date in clinical trials of different cancers, including PDAC (in combination with chemotherapy), head and neck squamous cell carcinoma (with an immune checkpoint inhibitor), ovarian cancer (with CAR-T cell therapy), colorectal cancer, and retinoblastoma (by intravitreal injection). More information on these clinical trials is available at Clinicaltrials.gov.

About Theriva Biologics, Inc.

Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s wholly-owned Spanish subsidiary Theriva Biologics, S.L., has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. In addition to VCN-01, the Company’s clinical-stage candidates include (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients); and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com.

Forward-Looking Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements regarding continuing to work closely with leading physicians and regulatory agencies to refine the Company’s clinical strategy for VCN-01 as an adjunct to chemotherapy in pediatric patients with advanced retinoblastoma and the potential benefits achievable from the grant of orphan drug designation. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to address the unmet medical needs for treatment of pediatric retinoblastoma, the Company’s ability to take advantage of the potential benefits of orphan drug designation, the Company’s ability to reach clinical milestones when anticipated, the Company’s product candidates demonstrating safety and effectiveness, as well as results that are consistent with prior results; the ability to complete clinical trials on time and achieve the desired results and benefits, continuing clinical trial enrollment as expected; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to promote or commercialize their product candidates for the specific indications, acceptance of product candidates in the marketplace and the successful development, marketing or sale of the Company’s products, developments by competitors that render such products obsolete or non-competitive, the Company’s ability to maintain license agreements, the continued maintenance and growth of the Company’s patent estate, the ability to continue to remain well financed and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

For further information, please contact:

Investor Relations:

Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608

Source: Theriva Biologics, Inc.


FAQ

What is the orphan medicinal product designation granted to Theriva Biologics (TOVX) for VCN-01?

The European Commission has granted orphan medicinal product designation to VCN-01, Theriva Biologics' lead clinical candidate, for the treatment of retinoblastoma.

What are the benefits of the orphan medicinal product designation for Theriva Biologics (TOVX)?

The designation provides benefits including 10-years market exclusivity in the EU upon marketing authorization, protocol assistance, administrative support, and reduced regulatory fees.

What is VCN-01 and what is it being developed for by Theriva Biologics (TOVX)?

VCN-01 is a systemic, selective, stroma-degrading oncolytic adenovirus being developed by Theriva Biologics for the treatment of retinoblastoma, particularly as an adjunct to chemotherapy in children.

Has Theriva Biologics (TOVX) conducted any clinical trials for VCN-01 in retinoblastoma?

Yes, Theriva Biologics has reported encouraging results from a Phase 1 trial evaluating the safety and activity of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma.

Theriva Biologics, Inc.

NYSE:TOVX

TOVX Rankings

TOVX Latest News

TOVX Stock Data

3.51M
2.54M
10.48%
21.21%
4%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
ROCKVILLE